PDCD1 and nasopharyngeal carcinoma: Early-phase clinical studies using anti-PD-1 immune checkpoint inhibitors in recurrent or metastatic NPC have reported incidence rates of hypothyroidism during immunotherapy, which were 18.5% for pembrolizumab [5], 6.7% for nivolumab [6], and 32% for camrelizumab [7].